We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety of Lactobacillus Reuteri in Healthy Volunteers

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00774163
First Posted: October 17, 2008
Last Update Posted: December 19, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
National Center for Complementary and Integrative Health (NCCIH)
Johns Hopkins Bloomberg School of Public Health
Asociación Benéfica Prisma
Information provided by (Responsible Party):
Richard A. Oberhelman, Tulane University School of Medicine
  Purpose
This is a phase one study to assess the safety of daily dosing of Lactobacillus reuteri in healthy adults in Peru. It is conducted as a preliminary study in support of a clinical trial to assess safety and efficacy of Lactobacillus reuteri versus placebo for treatment of pediatric diarrhea in Peru.

Condition Intervention Phase
Healthy Biological: Lactobacillus reuteri Other: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Phase 1: Safety of Lactobacillus Reuteri in Healthy Volunteers

Resource links provided by NLM:


Further study details as provided by Richard A. Oberhelman, Tulane University School of Medicine:

Primary Outcome Measures:
  • Number of Participants With a Positive Blood Culture for L. Reuteri [ Time Frame: participants were followed for an average of 36 days ]
    To assess association between administration of Lactobacillus reuteri (Lr) strain DSM 17938 and abnormal lab values (CBC, BUN, Creatinine, AST, ALT, blood culture).

  • Mean Daily Temperature [ Time Frame: 5 days of study product administration ]
    Measured daily during 5 days of study product administration

  • Leukocyte Count on Day 5 [ Time Frame: Measured on day 5 ]
  • Serum Alanine Aminotransferase (ALT) in Female Participants [ Time Frame: Day 5 ]
  • Serum ALT in Males [ Time Frame: Day 5 ]
  • Serum Aspartate Aminotransferase (AST) in Females [ Time Frame: Day 5 ]
  • Serum AST in Males [ Time Frame: Day 5 ]
  • Blood Urea Nitrogen [ Time Frame: Day 5 ]
  • Serum Creatinine [ Time Frame: Day 5 ]

Secondary Outcome Measures:
  • Number of Subjects With at Least One PCR Positive Stool Specimen [ Time Frame: Average of 36 day follow up period ]
  • Clinical Tolerance of Lactobacillus Reuteri (Lr) Strain DSM 17938 Based on Number of Days With Vomiting Reported [ Time Frame: Day 0 through 6 weeks after Day 0 ]
  • Clinical Tolerance of Lactobacillus Reuteri (Lr) Strain DSM 17938 Based on Number of Days With Pruritis Reported [ Time Frame: Day 0 through 6 weeks after Day 0 ]
  • Clinical Tolerance of Lactobacillus Reuteri (Lr) Strain DSM 17938 Based on Number of Days With Headache Reported [ Time Frame: Day 0 through 6 weeks after Day 0 ]
  • Clinical Tolerance of Lactobacillus Reuteri (Lr) Strain DSM 17938 Based on Number of Days With Malaise Reported [ Time Frame: Day 0 through 6 weeks after Day 0 ]
  • Clinical Tolerance of Lactobacillus Reuteri (Lr) Strain DSM 17938 Based on Number of Days With Diarrhea Reported [ Time Frame: Day 0 through 6 weeks after Day 0 ]
  • Clinical Tolerance of Lactobacillus Reuteri (Lr) Strain DSM 17938 Based on Number of Days With Myalgia Reported [ Time Frame: Day 0 through 6 weeks after Day 0 ]
  • Clinical Tolerance of Lactobacillus Reuteri (Lr) Strain DSM 17938 Based on Number of Days With Subjective Fever Reported [ Time Frame: Day 0 through 6 weeks after Day 0 ]

Enrollment: 45
Study Start Date: February 2010
Study Completion Date: October 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period
Biological: Lactobacillus reuteri
Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period
Other Name: BioGaia Probiotic Drops
Placebo Comparator: 2
Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period
Other: Placebo
5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period

Detailed Description:

This is a phase I blinded randomized study of the safety and tolerability of Lactobacillus reuteri DSM 17938 given daily for a period of five consecutive days. Upon enrollment subjects will be randomized to one of two treatment groups in a ratio of treatment to placebo of 2:1. Subjects will be randomized to receive either:

A. Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period that corresponds to a dose of the closely related L. reuteri ATCC 55730 strain that has shown to be therapeutic for infantile colic. The strain used in this study (DSM 17938) has been cured of an antibiotic resistance plasmid found in the original BioGaia strain (L. reuteri ATCC 55730).

B. Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period (BioGaia AB, Stockholm, Sweden).

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Adults 18-65 with no exclusion criteria
  • Subject is a male or, if the subject is female and of childbearing potential then she must have a negative serum or urine pregnancy test result within 48 hours of initiating study preparations and agree to use an acceptable method of contraception. Acceptable methods of contraception include depot forms of progesterone containing therapies or an intrauterine device (IUD).

Exclusion Criteria:

  • No enrollment of family members in households where any of the following are present:

    • Another study participant in the household
    • Pregnancy or current breastfeeding by any household member
    • Presence of an infant under age 6 months living in the household
    • Presence of immune suppressed individuals or use of immunosuppressive agents (corticosteroids, methotrexate) by any household member
    • Presence of a serious congenital anomaly or chronic medical condition that would contraindicate participation in any household member, including history of gastrointestinal surgery, chronic gastrointestinal illness, abnormal intestinal anatomy, or abnormal bowel functionality
  • Allergy to penicillin or cephalosporins
  • History of antibiotic use in the last 30 days
  • Use of probiotic products within the past 90 days
  • History of diarrheal illness within the past 30 days
  • Presence of fever or a pre-existing adverse event monitored in the study
  • Positive results on serum diagnostic tests for antibodies to HIV, Hepatitis B core antigen, and Hepatitis C.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00774163


Locations
Peru
Community of Santa Clara
Iquitos, Loreto, Peru
Sponsors and Collaborators
Tulane University School of Medicine
National Center for Complementary and Integrative Health (NCCIH)
Johns Hopkins Bloomberg School of Public Health
Asociación Benéfica Prisma
Investigators
Principal Investigator: Richard A Oberhelman, MD Tulane School of Public Health and Tropical Medicine
Study Director: Margaret N Kosek, MD Johns Hopkins Bloomberg School of Public Health
  More Information

Responsible Party: Richard A. Oberhelman, Professor, Tulane University School of Medicine
ClinicalTrials.gov Identifier: NCT00774163     History of Changes
Other Study ID Numbers: FDA IND# 13710
1R01AT002733-01A1 ( U.S. NIH Grant/Contract )
First Submitted: October 15, 2008
First Posted: October 17, 2008
Results First Submitted: June 13, 2012
Results First Posted: July 12, 2013
Last Update Posted: December 19, 2016
Last Verified: December 2016

Keywords provided by Richard A. Oberhelman, Tulane University School of Medicine:
probiotics
lactobacillus
reuteri
none (safety only)